Richard Burr: “As you can see, there's tremendous interest in this subject and the need for extended hearings...”

It is not for some, it is for all.

I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.

I oppose Ms. Kotagal's nomination and urge my colleagues to do the same.